Mechiche Alami S, Velard F, Draux F, Siu Paredes F, Josse J, Lemaire F, Gangloff S C, Graesslin O, Laurent-Maquin D, Kerdjoudj H
EA 4691 «Biomatériaux et Inflammation en Site Osseux», Pôle Santé, SFR CAP-Santé (FED 4231), Université de Reims Champagne-Ardenne, Reims, France UFR D'odontologie, URCA, Reims, France.
EA 4691 «Biomatériaux et Inflammation en Site Osseux», Pôle Santé, SFR CAP-Santé (FED 4231), Université de Reims Champagne-Ardenne, Reims, France Centre de Biologie Moléculaire, Université d'Aréquipa, Aréquipa, Pérou.
Biomed Mater Eng. 2014;24(1 Suppl):53-61. doi: 10.3233/BME-140974.
Stem cells are the most powerful candidate for the treatment of various diseases. Suitable stem cell source should be harvested with minimal invasive procedure, found in great quantity, and transplanted with no risk of immune response and tumor formation. Fetal derived stem cells have been introduced as an excellent alternative to adult and embryonic stem cells use, but unfortunately, their degree of "stemness" and molecular characterization is still unclear. Several studies have been performed deciphering whether fetal stem cells meet the needs of regenerative medicine. We believe that a transcriptomic screening of Wharton's jelly stem cells will bring insights on cell population features.
干细胞是治疗各种疾病最有力的候选者。合适的干细胞来源应以微创方式获取,数量丰富,且移植时无免疫反应和肿瘤形成风险。胎儿来源的干细胞已被作为成人和胚胎干细胞使用的一种极佳替代物引入,但不幸的是,它们的“干性”程度和分子特征仍不清楚。已经进行了几项研究来解读胎儿干细胞是否满足再生医学的需求。我们认为,对沃顿胶干细胞进行转录组学筛选将为细胞群体特征带来见解。